Introduction {#sec1}
============

Bioactive peptides are peptide compounds with low molecular weights and typically have significant biological activities.^[@ref1]^ Melittin (MET) is an α-helical active peptide with an amphiphilic structure and has various physiological activities such as antibacterial,^[@ref2],[@ref3]^ anti-inflammatory,^[@ref4],[@ref5]^ antitumor,^[@ref6],[@ref7]^ and antiviral activities.^[@ref8],[@ref9]^ It is valuable in a wide range of applications in the pharmaceutical, healthcare, cosmetics, and other industries.^[@ref10]−[@ref13]^

There are three methods for MET preparation: extraction from natural bee venom, chemical synthesis, and biological preparation.^[@ref14]^ MET is derived from European bee (*Apis mellifra*) venom and constitutes only half of the bee venom. The extraction of MET is achieved at the expense of bees' lives, which is not conducive to the continued development of bee colonies and beekeeping. Crude bee venom contains complex components with similar molecular weights, therefore MET isolation is challenging, cumbersome, and expensive.^[@ref14]^ In particular, natural extraction results in significant contamination of MET with lipases, which can interfere with the membranolytic activity of the peptide.^[@ref15]^ Chemical synthesis mainly uses amino acids as the raw materials and usually involves the synthesis of a polypeptide or protein by a solid-phase method. It has the disadvantages of causing serious pollution and giving a low target protein yield.^[@ref16]^ Neither natural extraction nor chemical synthesis is an efficient method for large-scale preparation of MET.

There are many reports on the preparation of active peptides by biological methods,^[@ref17]−[@ref19]^ and such methods have considerable development prospects. However, the preparation of MET by biological methods still presents great challenges. MET is not easily expressed because of its high toxicity to cells and low molecular weight (only 26 amino acids, a molecular weight of about 2.9 kDa). Moreover, MET is susceptible to protease degradation in bacteria and therefore cannot be directly expressed in prokaryotic systems. More importantly, MET expression is not easy because of its high toxicity against a broad range of bacteria.^[@ref2],[@ref3]^ Currently, MET is usually expressed in a fusion protein.^[@ref20]−[@ref26]^

MET has been expressed by a fusion method. The fused MET sometimes has inclusion bodies or low-level expression.^[@ref27],[@ref28]^ For example, the MET gene was directly linked to a soluble trimer of the tumor necrosis factor-related apoptosis-inducing ligand sTRAIL and expressed in *Escherichia coli*. This resulted in 90% of the inclusion bodies in the fusion protein sTRAIL-melittin.^[@ref28]^

Improvements in molecular biological techniques have enabled researchers to perform novel fusion expressions of MET. MET has been bound with other functional proteins to achieve the expression of a soluble form. Che et al.^[@ref25]^ connected the active domain of cecropin A and MET to the hypersensitive (HR)-elicitor Hpa1 of rice leaf spot bacteria by rational design from scratch in *E. coli*. A novel binding protein, Hcm1, was purified. This acts as a potential insecticide by inducing disease resistance against viral, bacterial, and fungal pathogens. Shin et al.^[@ref24]^ combined MET and gelonin genes to induce the expression of a MET-gelonin fusion protein in *E. coli*. They confirmed that the MET-gelonin toxin protein retained the equivalent intrinsic activity of MET and the inhibitory effect of unmodified gelonin on protein translation. Liu et al.^[@ref23]^ linked MET and mutant human interleukin 2 (MhIL-2) on the vector pET-15b in *E. coli* and successfully expressed a new fusion protein MET-MhIL-2. The fusion protein showed the functional activities of IL-2 and MET and inhibited tumor growth in vivo. Su et al.^[@ref22]^ fused MET with the amino-terminal fragment (ATF) of a urokinase-type plasminogen activator, which can target and recognize cancer cells. A pPICZαC-ATF-melittin eukaryotic expression vector was constructed and fusion proteins were expressed in *Pichia pastoris*, and an anticancer effect was detected in vitro after protein purification. Ishida et al.^[@ref26]^ used calmodulin (CaM) as a fusion partner for MET and inserted a His tag at the N-terminus to induce protein expression in *E. coli*. The soluble fusion protein CaM-MET was obtained. After purification with a Ni column and subsequent digestion with TEV protease, 2.5 mg/mL of purified MET was collected by high-performance liquid chromatography (HPLC). However, they did not verify the antibacterial activity of the purified MET.

The glutathione-S-transferase (GST) tag is usually selected for fusion protein expression because it can help to protect against intracellular protease cleavage and stabilize recombinant proteins.^[@ref29]^ Buhrman et al.^[@ref30]^ achieved active peptide expression by constructing the plasmid pJB-HTS-MET to express GST and His-tagged MET in *E. coli* Rosetta cells. However, most of the MET was insoluble. Rayahin et al. produced MET in fusion with GST but did not cleave GST, which retained anti-inflammatory properties. Shi et al.^[@ref31]^ further cleaved GST from MET using thrombin. The purified melittin with up to 90% of purity preserves the antigenicity and functionality of the protein. MET expression and purification from a fusion protein is still a challenge. To the best of our knowledge, there is no industrial biological method for preparing active MET. The preparation of soluble MET and improvement of its yield by biosynthetic methods would therefore have social and economic benefits.

In this work, we fused the MET peptide with a GST tag and achieved high heterologous expression of the fusion protein GST-MET in *E. coli*. More importantly, we purified the fusion protein GST-MET and obtained the active pure peptide MET with no tags. The antibacterial activities of recombinant MET (rMET) against *E. coli*, *Bacillus pumilus,* and *Staphylococcus pasteuri* were found to be almost the same. The successful expression, purification, and characterization of MET provides a novel approach to the biological preparation of MET and serves as a good example of active peptide biosynthesis. More importantly, the biosynthesis of MET will reduce the sacrifice of bee colonies that result from MET extraction from bee venom.

Results and Discussion {#sec2}
======================

Overexpression of Fusion Proteins GST-proMET and GST-MET {#sec2.1}
--------------------------------------------------------

Promelittin (proMET) is a natural precursor of MET. It has a molecular weight of 7.6 kDa and contains a signal peptide, a leader peptide, and a mature peptide (2.9 kDa). In the biosynthesis by honeybees, the mature peptide is released after cleavage of the signal peptide and the leader peptide to form MET.^[@ref34]^ Because MET is lethal to bacterial cells, it is usually expressed in a fusion protein by combining MET with another protein tag. The GST tag is widely used to promote the solubility and folding of recombinant proteins.^[@ref35],[@ref36]^ In this work, we used the expression plasmid pGEX-6P-1 and GST fusion with the target peptide MET.

As described in the Materials and methods section, the two recombinant strains *E. coli* BL21/pGEX-proMET and *E. coli* BL21/pGEX-MET were obtained. Protein expression was optimized by the optimization of the temperature and isopropyl-β-[d]{.smallcaps}-thiogalactoside (IPTG) concentration. SDS-PAGE results ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) showed that GST-proMET was expressed in the sediment, consistent with its theoretical molecular weight of 35 kDa. The protein GST-proMET was not observed in cell-free extracts of *E. coli* BL21/pGEX-proMET. These results suggest that GST-proMET is mainly expressed in the insoluble form. In contrast, GST-MET was expressed in the supernatant by induction with 0.1 mM IPTG at 25 °C; the band size was consistent with the theoretical molecular mass of 30 kDa ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). A band at about 30 kDa was also observed in the sediment of *E. coli* BL21/pGEX-MET. These results show that the fusion protein GST-proMET could not be expressed, whereas GST-MET was partially expressed as a soluble protein with about 15% of the total soluble proteins (∼20 mg/L culture). It was reported that the presence of signal peptides and leader peptides generally had positive effects on the expression or folding of the core peptide.^[@ref37],[@ref38]^ However, their presence sometimes led to high expression levels that might cause the target protein to accumulate in the cell and be expressed as inclusion bodies.^[@ref39]^ In the expression of GST-proMET, the corresponding bands in the sediment were thick, which indicates that GST-proMET was strongly expressed, and therefore, inclusion bodies were formed because of overaccumulation.

![(A) Expression of proMET in *E. coli* BL21/pGEX-proMET. M, Protein Molecular Weight Marker (Low); Lane 1, total proteins of *E. coli* BL21/pGEX-6p-1 before induction; Lanes 2 and 3, soluble and insoluble proteins of *E. coli* BL21/pGEX-6p-1 after induction by 0.1 mM IPTG; Lanes 4--6, total, soluble, and insoluble proteins from *E. coli* BL21/pGEX-proMET after induction by 0.1 mM IPTG. (B) Expression of MET in *E. coli* BL21/pGEX-MET. M, Protein Molecular Weight Marker (Low); Lane 1, total protein from *E. coli* BL21/pGEX-MET before induction; Lanes 2--4: total, soluble, and precipitated proteins of *E. coli* BL21/pGEX-MET after induction by 0.1 mM IPTG.](ao0c00085_0003){#fig1}

Purification of Fusion Protein GST-MET {#sec2.2}
--------------------------------------

We purified the fusion protein GST-MET using glutathione sepharose high-performance affinity chromatography. Most untagged *E. coli* proteins were removed by washing, and the fusion protein was eluted with 10 mM reduced glutathione. The GST protein was also purified for comparison. The purity of the protein was determined by SDS-PAGE. As shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A, lane 3, a band at 27 kDa represented purified GST, whereas GST-MET gave two bands at about 27 and 30 kDa (lanes 2 and 4). The lower band was consistent with the molecular mass of GST. This is possible because GST-MET expression simultaneously induced overexpression of GST. After purification and enrichment by glutathione sepharose high-performance affinity chromatography, a clear band that was consistent with the molecular mass of GST was observed on the SDS-PAGE gel. It can be deduced that this portion of the GST will affect the binding rate of the target fusion protein GST-MET to glutathione sepharose high-performance medium during the purification process.

![(A) Tris-SDS-PAGE analysis of purification of GST-MET and GST with glutathione-affinity chromatography; M, Protein MW Marker (Low); Lanes 1 and 2, soluble proteins from *E. coli* BL21/pGEX-6p-1 and *E. coli* BL21/pGEX-MET; Lanes 3 and 4, the elution of GST and GST-MET by 10 mM reduced glutathione elutes GST; (B) The digestion of GST-MET with different concentrations of PPase. Lane 1, GST-MET before the digestion; Lanes 2--5, the digestion of GST-MET under the treatment of different concentration ratios of GST-MET and PPase: 10:1, 5:1, 2.5:1, and 1:1. (C) Tricine-SDS-PAGE analysis of MET purification with glutathione sepharose high-performance medium. M1, protein molecular weight marker (Low); M2, ultralow molecular weight protein marker; Lane 1, before digestion; Lane 2, the purified MET.](ao0c00085_0008){#fig2}

The purified fusion protein GST-MET was digested overnight with PPase in glutathione sepharose high-performance medium. The purified GST-MET was digested overnight at 4 °C with PPase of different concentrations. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B shows that when the concentration ratio of GST-MET to PPase was 10:1, 5:1, 2.5:1, or 1:1, the band at 30 kDa, which is consistent with the molecular weight of GST-MET, almost disappeared. The two bands at 30 and 27 kDa were replaced by one band at 27 kDa, which indicates that GST-MET was completely digested by PPase. However, the band for MET (at about 3 kDa) was not observed in SDS-PAGE. These results are attributed to the difference between the molecular sizes of GST and MET after the digestion of GST-MET by PPase. The relative molecular weight of MET was only 3 kDa, and that of the GST label was 27 kDa. Their different molecular weights might affect the SDS-PAGE analysis results.

The GST tag was removed and the PPase was retained in the target protein MET by centrifuging the glutathione sepharose high-performance medium at 5000*g* for 5 min. The protein of interest, i.e., MET, was in the supernatant, and the GST tag protein and GST-tagged PPase were bound to the medium. The results of Tricine-SDS-PAGE analysis ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C) show that some of the GST tag and GST-tagged PPase remained in the supernatant.

After centrifugation at 10 000*g* for 30 min, the supernatant was loaded on Superdex Peptide 10/300 GL equilibrated with buffer A3. An ÄKTA purifier was used to measure the UV absorption at 215 nm, and peak samples were collected for analysis by Tricine-SDS-PAGE and SDS-PAGE (18%). The peak sample collected after elution of about 15 mL showed a band with a molecular weight of 3 kDa ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A--C), which is consistent with the size of pure rMET. The rMET was purified to apparent homogeneity by SDS-PAGE. Calculations of the corresponding *A*~215~ value and SDS-PAGE analysis value showed that about 15% of the rMET was in peak 1 and about 85% was in peak 2. Further experiments were performed on the rMET in peak 2. After several chromatography procedures, about 5.8% rMET (∼3.5 mg/L culture) of purity greater than 90% was obtained. Mass spectrometric analysis showed the presence of cMET of molecular mass 2847.5 and 98% purity; the rMET in peak 2 had a molecular mass of 3447.2 Da and a purity of about 92% ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![Purification of MET using Superdex Peptide 10/300 GL chromatography. (A) Chromatogram of Superdex peptide 10/300 GL; (B) Tricine-SDS-PAGE analysis of the peak sample. M, ultralow molecular weight protein Marker; Lane 1, the sample before loading; Lane 2, the sample of peak 1; Lane 3, the concentrated sample of peak 2; Lane 4, cMET; (C) SDS-PAGE analysis of rMET in peak 2 and cMET.](ao0c00085_0001){#fig3}

![Identification of (A) rMET and (B) cMET by mass spectrometry.](ao0c00085_0002){#fig4}

Determination of Antibacterial Activity of rMET {#sec2.3}
-----------------------------------------------

MET has antibacterial activity because it destroys bacterial membranes, and it is often used as a model antibacterial agent.^[@ref40]^ The antibacterial activity of pure rMET was determined by Oxford cup experiments with *E. coli* JM109, *B. pumilus*, and *S. pasteuri* as test strains. As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A--C, the three cultured bacteria were treated with rMET (100 μL, 50 μg/mL). The inhibition zone of *B. pumilus* was significantly larger than those of *E. coli* and *S. pasteuri*. The inhibition zone of rMET against *E. coli* was the smallest among the three strains. These results show that the purified rMET had significant antibacterial effects against *E. coli*, *B. pumilus*, and *S. pasteuri*.

![Bacteriostatic tests of rMET against *E. coli* JM109 (A), *B. pumilus* (B), and *S. pasteuri* (C) and antibacterial activity of rMET (D). (A), (B), and (C) are the bacteriostatic tests by adding 100 μL of rMET of 50 μg/mL against *E. coli* JM109, *B. pumilus,* and *S. pasteuri*, respectively. 1, rMET; 2, cMET; 3, ddH~2~O; 4. Ampicillin. (D) Antibacterial activity of rMET against *E. coli*, *B. pumilus,* and *S. pasteuri*. Bacteria were incubated in LB liquid medium and treated with 5 μg/mL rMET, 5 μg/mL cMET, and 10 μg/mL ampicillin. Percentage of growth was calculated relative to untreated samples, commercial cMET, and commercial antibiotics. Untreated, nondose; rMET, recombinant MET; cMET, commercial synthesized MET; and Amp, ampicillin.](ao0c00085_0004){#fig5}

The antibacterial activities of rMET in inhibition of the growth of Gram-negative *E. coli* JM109 and Gram-positive *B. pumilus* and *S. pasteuri* were further tested in 96-well microplates containing LB broth. As shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}, rMET and cMET significantly inhibited *B. pumilus* growth at a concentration of 5 μg/mL. *B. pumilus* was the most susceptible to rMET and showed growth inhibition rates of 97% by rMET and 100% by cMET ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D). For *S. pasteuri*, rMET gave 68.6% growth inhibition compared with 72.7% by cMET. Ampicillin (10 μg/mL) showed only 49.9% growth inhibition of *E. coli*, whereas 5 μg/mL rMET was sufficient to inhibit about 52.5% growth of *E. coli*; inhibition by cMET was about 63%. These results indicate that the antibacterial effects of rMET on Gram-positive strains were significantly higher than those on Gram-negative strains. The antibacterial activities of cMET and rMET were similar and the same antimicrobial activities were obtained against Gram-positive *B. pumilus* and *S. pasteuri*.

These evaluations enabled the determination of the minimum inhibitory concentrations (MICs) of rMET and cMET for the bacterial species studied. As shown by the data in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, the sensitivity of *B. pumilus* to rMET is greater than those of *E. coli* and *S. pasteuri*. The MIC for *B. pumilus* is about sixfold lower than that for *E. coli* and 5.5-fold lower than that for *S. pasteuri*. The MIC of rMET is slightly higher than that of cMET against the three bacterial species. This suggests that the bacterial resistance for rMET is similar to that for cMET.

###### Minimum inhibitory concentration (MIC) of recombinant melittin (rMET) and commercial melittin (cMET) against *E. coli*, *B. pumilus,* and *S. pasteuri*

  bacterial species   MIC (μg/mL)   
  ------------------- ------------- ------------
  *E. coli*           41.0--43.5    40.0--42.5
  *B. pumilus*        6.5--8.0      6.0--7.5
  *S. pasteuri*       35.5--37.0    33.0--35.0

Analysis of the rMET Protein Structure {#sec2.4}
--------------------------------------

The antibacterial activity of purified rMET did not obviously differ from that of cMET, and therefore, further structural analysis was required. After purification, there are five more amino acid residues encoded by the plasmid at the N-terminus of rMET, i.e., Gly--Pro from the protease cleavage site, Leu in the middle, and Gly--Ser encoded by the recognition sequence of *Bam*H I. A comparison of the sequences of native MET (GIGAVLKVLTTGLPALISWIKRKRQQ) and rMET (GPLGSMGIGAVLKVLTTGLPALISWIKRKRQQG) shows that six N-terminal amino acids and one C-terminal residue are different. The circular dichroism spectroscopic assay of the rMET and cMET spectra showed a similar trend in appearance, indicating that their secondary structures are similar. The residue ellipticities of rMET and cMET were 14.03 × 10^--4^ and 14.21 × 10^--4^ ° cm^2^/dmol, respectively at 197 nm ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}).

![Circular dichroism analysis of rMET and cMET.](ao0c00085_0005){#fig6}

Conclusions {#sec3}
===========

In summary, we heterologously expressed the fused protein GST-MET in *E. coli* and purified it by several chromatography steps. Recombinant MET, i.e., rMET, of purity over 90% was obtained. The antibacterial activities of rMET against Gram-positive *B. pumilus* and *S. pasteuri* were almost the same as those of cMET, but the activity was slightly lower against Gram-negative *E. coli*. This study provides a novel approach to the heterologous expression of active peptides and provides a good example for future biological preparations of active peptides. Further toxicological experiments will be performed to study the effects of the five amino acid residues at the N-terminus of rMET. Other biosystems for MET expression such as *B. subtilis*, which do not produce toxins, will be constructed to improve the production of rMET.

Experimental Section {#sec4}
====================

Microorganisms and Chemicals {#sec4.1}
----------------------------

*Escherichia coli* JM109 (DE3) and *E. coli* BL21 (DE3) were purchased from Invitrogen (Carlsbad, CA). Commercial melittin (cMET, 98%) was purchased from GenScript Co., Ltd. (Nanjing, China). PrimeStar Max (Premix), r*Taq* DNA polymerase, restriction enzymes, T4 DNA ligase, DNA marker, protein molecular weight marker, and pMD19-T vector were purchased from Takara (Dalian, China). Primers and the melittin (MET) gene were synthesized by Shanghai Sangon Biotechnology Co. (Shanghai, China). Plasmid Mini kit I and the gel extraction kit were purchased from Omega Bio-Tek (USA). Expression vector pGEX-6p-1 was purchased from Wuhan Miaoling Biological Technology Co., Ltd. (Wuhan, China). The type of centrifuge was Eppendorf Centrifuge 5810 R, and the rotor was F-34-6-38 (Germany).

Construction of Expression Vectors {#sec4.2}
----------------------------------

The MET propeptide gene *promet* containing a signal peptide, a leader peptide, and a mature peptide sequence was chemically synthesized. To construct the recombinant plasmid pGEX-proMET, the gene *promet* fragment was amplified with primer 1 and primer 2 ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) using the following PCR program: 98 °C predenaturation for 30 s, thirty cycles with incubation for 15 s at 98 °C, 25 s at 55 °C, and 30 s at 72 °C, followed by termination at 72 °C for 10 min. The purified proMET fragments were cloned into vector pMD19-T to construct pMD19T-proMET. The positive clones were selected and incubated in LB liquid medium supplemented with 100 μg/mL ampicillin and confirmed by DNA sequencing in Tianlin Biotechnology Co., Ltd. (Wuxi, China). Then, the fragment *promet* with the *Bam*H I/*Not* I site was cloned into the corresponding site of expression vector pGEX-6p-1 to construct pGEX-proMET ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}). The HRV protease cleavage site in the vector pGEX-6p-1 was between LEVLFQ and GP.

![Schematic diagram of pGEX-proMET and pGEX-MET plasmid construction.](ao0c00085_0006){#fig7}

###### Primers, plasmids, and strains used in this study[a](#t2fn1){ref-type="table-fn"}

  strains/plasmids/primers     characteristics                                           sources
  ---------------------------- --------------------------------------------------------- ------------
  Strains                                                                                 
  *E. coli* JM109              cloning host, antibacterial activity test                 Invitrogen
  *E. coli* BL21 (DE3)         expression host                                           Invitrogen
  *B. pumilus*                 antibacterial activity test                               lab stock
  *S. pasteuri*                antibacterial activity test                               lab stock
  *E. coli* JM109/T-proMET     *E. coli* JM109 harboring T-proMET                        this study
  *E. coli* BL21/pGEX-proMET   *E. coli* BL21 harboring pGEX-proMET                      this study
  *E. coli* BL21/pGEX-MET      *E. coli* BL21 harboring pGEX-MET                         this study
  Plasmids                                                                                
  pMD19-T                      cloning vector                                            Takara
  pGEX-6p-1                    expression vector                                         lab stock
  T-proMET                     pMD19-T harboring *promet* gene                           this study
  pGEX-proMET                  pGEX-6p-1 harboring *promet* gene                         this study
  pGEX-MET                     pGEX-6p-1 harboring *met* gene                            this study
  Primers                      sequences (5′ → 3′)                                       
  primer 1                     CGC[GGATCC]{.ul}ATGAAATTCCTGGTTAACGTTGCTCTGG (*Bam*H I)   
  primer 2                     TT[GCGGCCGC]{.ul}TTAACCCTGCTGACGTTTACGTTTGATC (*Not* I)   
  primer 3                     CAGGGGCCCCTGGGATCCATGGGTATCGGTGCTGTTCTGAAAGTTCTG          
  primer 4                     AGAACAGCACCGATACCCATGGATCCCAGGGGCCCCTGGAACAGAACTTCC       

The underlined bases are the restriction endonuclease recognition sequences.

The recombinant plasmid pGEX-MET was amplified using pGEX-proMET as a template and primer 3 and primer 4 as primers ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). After the amplified fragment was digested with *Dpn* I enzyme, it was transformed into *E. coli* JM109. The recombinant plasmid pGEX-MET was obtained after nucleotide sequencing. The constructed recombinant plasmids pGEX-proMET and pGEX-MET were transformed into *E. coli* BL21 (DE3) to obtain the recombinant strains *E. coli* BL21/pGEX-proMET and *E. coli* BL21/pGEX-MET.

Protein Expression {#sec4.3}
------------------

The recombinant *E. coli* BL21/pGEX-proMET and *E. coli* BL21/pGEX-MET were cultured in LB broth containing 100 μg/mL ampicillin with shaking at 37 °C. When the OD~600~ value of the culture was about 0.6, 0.1--0.5 mM isopropyl β-[d]{.smallcaps}-thiogalactoside (IPTG) was added to induce protein expression at 20--37 °C for 16 h. The cells were harvested by centrifugation at 8000*g* for 10 min and resuspended in buffer A1 (140 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, 1.8 mM KH~2~PO~4~, pH 7.3), and lysed by sonication at 4 °C. The supernatant was collected by centrifugation at 10 000*g* for 45 min. The samples were analyzed by 9% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Soluble expressed proteins were used for subsequent purification.

Purification of Fusion Protein GST-MET {#sec4.4}
--------------------------------------

Glutathione Sepharose High-Performance medium (GE Healthcare, Piscataway, NJ) was equilibrated with buffer A1. The supernatants were filtered with a 0.22 μm microporous membrane, and then they were loaded onto the resin at a speed of 1 mL/min. The column was washed with 10 mL of buffer A1 to eliminate unbound proteins. The protein was eluted with buffer B1 (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0). The eluted fractions were collected for SDS-PAGE analysis.

Purification and Pure MET {#sec4.5}
-------------------------

After the hybrid protein in the supernatant was washed, the fusion protein GST-MET in Glutathione Sepharose High-Performance medium was treated with Prescission protease (PPase) in buffer A2 (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, pH 7.5) at 4 °C overnight.

After digestion, to remove the GST-tagged protein and the PPase from the target protein, the medium was segmented by centrifugation at 500*g* for 5 min. The supernatant was collected for size-exclusion chromatography.

Superdex Peptide 10/300 GL (GE Healthcare, Piscataway, NJ) was equilibrated with the A3 buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) with an ÄKTA purifier system. The collected samples were centrifuged at 10 000*g* for 30 min to remove insoluble matter, and then the supernatant was loaded in Superdex Peptide 10/300 GL. The column was eluted with buffer A3 at room temperature. UV absorption was measured at UV 215 nm, and the elution peaks were collected for Tricine-SDS-PAGE^[@ref32]^ with 18% polyacrylamide analysis.

Antibacterial Activity Determination {#sec4.6}
------------------------------------

Bacterial cultures were grown in aerobic conditions to the mid-log phase as determined when the OD~600~ was 0.5. Then, 1 mL of the bacterial solution was diluted in 200 mL of agar medium kept at 50 °C, and 5 mL was quickly added to the plate to be flattened. After the upper medium was solidified, the sterilized Oxford cup (8 × 6 × 10 mm^3^) stands vertically near the flat plate mark. The purified rMET and chemically synthesized MET (cMET) of 50 μg/mL were added to the Oxford Cup, ampicillin was used at 200 μg/mL as a positive control, and ddH~2~O was used as a negative control. The plate was incubated at 37 °C for 16--18 h. The inhibition zones were observed.

*E. coli*, *B. pumilus,* and *S. pasteuri* were selected to culture in LB liquid medium to the logarithmic growth phase. Approximately 2 × 10^6^ colony forming units (CFU) per mL of each strain were incubated in a 96-well microplate (Thermo Fisher Scientific, China) with rMET or cMET. The final concentration of rMET or cMET was 5 μg/mL in each well. Untreated strains cultured in LB served as blank controls. Ampicillin (10 μg/mL) was used as a control for growth inhibition. Cultures were incubated at 37 °C for 2 h and monitored by counting live colonies (CFU) on LB agar medium by serial 10-fold dilutions.

For the determination of minimum inhibitory concentration (MIC), the microdilution technique was used.^[@ref33]^ Melittin was dissolved in sterile water and filtered using a 0.22 μm syringe filter. Bacteria (200 μL) were added to the diluted samples (20 ml) in 96-well plates. The microplates were incubated at 37 °C for 24 h. The MIC value was determined visually by comparison of bacterial growth with positive control. The MIC was between the lowest concentration capable of promoting inhibition of bacterial growth and the lowest concentration that did not promote inhibition. The experiments were performed in triplicate.

Mass Spectrum and Circular Dichroism {#sec4.7}
------------------------------------

Mass spectral measurement was performed using Waters MALDI SYNAPT G2-Si MS (Milford). Circular dichroism (CD) assays were performed using a Jasco J720 spectropolarimeter (JASCO, Inc., Easton, MD). Wavelength scan data were collected from 170 to 350 nm in a phosphate buffer (pH 7.5) for every 30 scans with the following settings: response, 1 s; sensitivity, 100 mdeg; and speed, 50 nm/min.
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